Abstract

Adenosine is a potent immunosuppressive purine metabolite contributing to the pathogenesis of solid tumors. Extracellular adenosine signals on tumor-infiltrating NK cells to inhibit their proliferation, maturation, and cytotoxic function. Cytokine priming imparts upon NK cells distinct activation statuses, which modulate NK anti-tumor immunity and responses to purinergic metabolism. Here, for the first time, we investigated human NK cell responses to adenosinergic signaling in the context of distinct cytokine priming programs. NK cells were shown to be hyper-responsive to adenosine when primed with IL-12 and IL-15 compared to IL-2, exhibiting enhanced IFN-γ expression from CD56bright and CD56dim subsets while modulating the expression of activation marker NKG2D. These responses resulted in signaling that was dependent on mTOR. Adenosine induced upregulation of transcriptional signatures for genes involved in immune responses while downregulating cellular metabolism and other protein synthesis functions that correlate to inhibited oxidative phosphorylation and glycolysis. Overall, our findings show that adenosine acts on specific cellular pathways rather than inducing a broad inhibition of NK cell functions. These responses are dependent on cytokine priming signatures and are important in designing therapeutic interventions that can reprogram NK cell immunometabolism for improved immunotherapies of solid tumors.

Highlights

  • Natural killer (NK) cells are powerful effectors of innate immunity

  • When NK cells were stimulated with IL-15 (100 ng/ml), we observed a significant increase in the level of expressed IFNγ in response to ADO (Figure 2B) from both CD56bright and CD56dim NK cells

  • The percentage of IFN-γ+ NK cells increased following ADO treatment (Figures S2A,B).We investigated changes in the phosphorylation of STAT5 at Y694 and ribosomal protein s6 at residues S235 and S236 for these activation programs in the presence of the same concentration of ADO

Read more

Summary

Introduction

Natural killer (NK) cells are powerful effectors of innate immunity. Immunotherapies utilizing genetically-engineered NK cells are showing promise in clinical settings [1], clinical treatment of solid tumors has lagged behind that of hematologic malignancies [2, 3]. Unlike T cells, NK cell function is driven by a balance of activating and inhibitory receptors through which they interact with pathogens by recognizing major histocompatibility complex (MHC) class I molecules on cancer cells [4]. The largest group of NK cell receptors includes natural killer group 2 (NKG2), which includes NKG2A, B, C, D, E, F, and H. Except NKG2A and B, all receptors are activating In pathogenic environments, such as in solid tumors, expression of activating receptors may be impaired, leading to suppression of NK cell anti-tumor immunity [5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call